FDA Drug recall D-0241-2026
Merck Emend (aprepitant) for oral suspension, 125 mg, Single-Dose Kit, Rx Only, Manufactured for: Merck Sharpe & Dohme LLC, Rahway, NJ 0706…
- FDA Drug
- Class II
- ongoing
- Published 2025-12-31
On 2025-12-31 the FDA classified a Class II recall of Merck Emend (aprepitant) for oral suspension, 125 mg, Single-Dose Kit, Rx Only, Manufactured for: Merck Sharpe & Dohme LLC, Rahway, NJ 0706… by Merck Sharp And Dohme, citing presence of particulate matter: potential presence of metal particulates in the product.
Read the official FDA Drug notice
| Agency | FDA Drug |
|---|---|
| Recall number | D-0241-2026 |
| Classification | Class II |
| Status | ongoing |
| Initiated | 2025-12-12 |
| Published | 2025-12-31 |
| Last updated | 2026-09-13 11:52 UTC |
| Company | Merck Sharp And Dohme |
| Distribution | US |
Product
Merck Emend (aprepitant) for oral suspension, 125 mg, Single-Dose Kit, Rx Only, Manufactured for: Merck Sharpe & Dohme LLC, Rahway, NJ 07065, USA, Manufactured by: Novo Nordisk Production Ireland Limited Athlone, Ireland, NDC 0006-3066-03
Reason
Presence of particulate matter: potential presence of metal particulates in the product.
Identifiers
| ndc | 0006-0461-02 |
|---|---|
| ndc | 0006-0461-01 |
| ndc | 0006-0461-06 |
| ndc | 0006-0461-12 |
| ndc | 0006-0462-01 |
| ndc | 0006-0462-06 |
| ndc | 0006-3862-03 |
| ndc | 0006-3862-13 |
| ndc | 0006-0464-01 |
| ndc | 0006-0464-10 |
| ndc | 0006-0464-05 |
| ndc | 0006-3066-01 |
| ndc | 0006-3066-03 |
| code_info | Lot #: Z014503, Exp 11/15/2027 |
Status history
No status changes recorded since RecallRadar first saw this recall on 2026-09-13 11:52 UTC. Current status: ongoing.
Source
Official record: https://api.fda.gov/drug/enforcement.json?search=recall_number:%22D-0241-2026%22
RecallRadar indexes public recall notices from the FDA, USDA FSIS, and CPSC. The official agency notice is the authoritative source. Always confirm details at the linked source before acting.